What is the 13F Pro Quality Score for XCUR?

13F Pro ranks EXICURE, INC. (XCUR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XCUR's current score at https://13fpro.ai/research/XCUR (free sign-up required for the full ranking).

Where does 13F Pro source XCUR data?

All EXICURE, INC. fundamentals and ownership data come directly from SEC EDGAR. EXICURE, INC. files with the SEC under CIK 1698530. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XCUR in?

EXICURE, INC. (XCUR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XCUR research updated on 13F Pro?

XCUR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

EXICURE, INC.(XCUR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1698530 XCUR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $28.8M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

XCUR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for EXICURE, INC. (XCUR), a Healthcare sector company. XCUR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $28.8m in revenue. Based on the latest XBRL financial filings (Q1 2026), EXICURE, INC. reports net income of $-1.8M, free cash flow of $-1.1M. Top institutional holders of XCUR by reported 13-F value include Carlyle Group, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XCUR trades on the Nasdaq exchange and files with the SEC under CIK 1698530. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XCUR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXICURE, INC. directly from SEC EDGAR. EXICURE, INC.'s 13F Pro composite quality score has ranged between 5 and 27 since 2021, currently 7.6 — a declining long-term trajectory across 10 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-1.8M

Free Cash Flow

Q1 2026

$-1.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $28.8MFY23 $0.00FY24 $500.0KFY25 $0.00

Net Income

+49.0% YoY

$-4.9MFY 2025

FY22 $-2.6MFY23 $-16.9MFY24 $-9.7MFY25 $-4.9M

Operating Income

+65.4% YoY

$-4.2MFY 2025

FY22 $-1.8MFY23 $-15.0MFY24 $-12.2MFY25 $-4.2M

EPS (Diluted)

+83.4% YoY

$-0.79FY 2025

FY22 $-0.56FY23 $-10.55FY24 $-4.75FY25 $-0.79

Total Assets

-6.7% YoY

$14.0MFY 2025

FY22 $23.3MFY23 $11.6MFY24 $15.1MFY25 $14.0M

Total Debt

—FY 2025

FY22 $0.00FY23 $0.00FY24 —FY25 —

Op. Cash Flow

-194.0% YoY

$-8.6MFY 2025

FY22 $-35.7MFY23 $-10.4MFY24 $-2.9MFY25 $-8.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$0.00 -100.0%	$500.0K	$0.00 -100.0%	$28.8M +73.5%	$16.6M +1181.9%	$1.3M
Net Income	$-4.9M +49.0%	$-9.7M +42.6%	$-16.9M -555.1%	$-2.6M +89.5%	$-24.7M +6.2%	$-26.3M
Operating Income	$-4.2M +65.4%	$-12.2M +18.4%	$-15.0M -719.0%	$-1.8M +92.8%	$-25.4M +4.4%	$-26.6M
EPS (Diluted)	$-0.79 +83.4%	$-4.75 +55.0%	$-10.55 -1783.9%	$-0.56 -1607.3%	$-0.03	—
Total Assets	$14.0M -6.7%	$15.1M +30.0%	$11.6M -50.4%	$23.3M -76.8%	$100.4M -12.9%	$115.3M
Total Debt	—	—	$0.00	$0.00 -100.0%	$16.6M +67.1%	$9.9M
Operating Cash Flow	$-8.6M -194.0%	$-2.9M +71.9%	$-10.4M +71.0%	$-35.7M +9.2%	$-39.3M -3081.8%	$1.3M

AI Insight: XCUR Financial Trends

XCUR remains pre-revenue with accelerating cash burn and equity depletion; Q1 2026 equity halved versus Q1 2025.

• Revenue remains at $0M across all eight quarters; company has not achieved commercialization.

• Equity declined from $11M in Q1 2025 to $2M in Q1 2026—an 82% contraction over one year.

• Operating cash burn averaged $2M per quarter in 2025; Q1 2026 burn moderated to $1M.

⚠ Equity runway critically low at $2M; no debt disclosed, implying imminent financing need or dilution.

⚠ Q1 2025 showed brief profitability ($3M net income); Q1 2026 returned to $2M loss—no sustained improvement.

AI Insight: XCUR Ratio Trends

Exicure remains deeply unprofitable with ROA oscillating between -22.5% and -82.6%—no path to profitability visible in available data.

• ROA deteriorated from -22.5% in Q2 2024 to -76.7% TTM (Mar 2026), signaling persistent operational losses.

• ROE swung wildly: +105.8% in Q1 2025, then collapsed to -140.7% by Q3 2025, reflecting erratic equity-base dynamics.

⚠ Q1 2025 showed anomalous positive ROE (+105.8%) and ROA (+58.2%)—verify if one-time gain or sustainable inflection.

⚠ Latest quarter ROA of -57.3% (Q1 2026) slightly better than Q4 2025 (-82.6%), but trend remains deeply negative.

Get alerted when XCUR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for EXICURE, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XCUR

Carlyle Group Inc.
$239.6K56,328 sh
GEODE CAPITAL MANAGEMENT, LLC
$157.6K36,913 sh
VANGUARD CAPITAL MANAGEMENT LLC
$140.8K32,983 sh
VANGUARD FIDUCIARY TRUST CO
$56.2K13,161 sh
NORTHERN TRUST CORP
$45.5K10,686 sh
NORTHWESTERN UNIVERSITY
$44.4K10,430 sh
BlackRock, Inc.
$39.8K9,353 sh
UBS Group AG
$3.7K866 sh
Tower Research Capital LLC (TRC)
$2.1K489 sh
MORGAN STANLEY
$672.00158 sh

Fund	Value	Shares
Carlyle Group Inc.	$239.6K	56,328
GEODE CAPITAL MANAGEMENT, LLC	$157.6K	36,913
VANGUARD CAPITAL MANAGEMENT LLC	$140.8K	32,983
VANGUARD FIDUCIARY TRUST CO	$56.2K	13,161
NORTHERN TRUST CORP	$45.5K	10,686
NORTHWESTERN UNIVERSITY	$44.4K	10,430
BlackRock, Inc.	$39.8K	9,353
UBS Group AG	$3.7K	866
Tower Research Capital LLC (TRC)	$2.1K	489
MORGAN STANLEY	$672.00	158

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XCUR on your watchlist

Track score changes the day EXICURE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XCUR a good stock to buy?

13F Pro's AI-powered analysis of EXICURE, INC. (XCUR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XCUR are available on the XCUR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XCUR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XCUR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EXICURE, INC.'s investment landscape.